Get the Stockscreener App
2.41
2.99%
0.07
Pre-market:
2.48
0.07
+2.90%
Organogenesis Holdings Inc stock is traded at $2.41, with a volume of 1.12M.
It is up +2.99% in the last 24 hours and up +0.00% over the past month.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
See More
Previous Close:
$2.34
Open:
$2.385
24h Volume:
1.12M
Relative Volume:
0.81
Market Cap:
$310.11M
Revenue:
$514.70M
Net Income/Loss:
$2.72M
P/E Ratio:
-15.17
EPS:
-0.1589
Net Cash Flow:
$17.08M
1W Performance:
+1.26%
1M Performance:
+0.00%
6M Performance:
-50.10%
1Y Performance:
-21.50%
1-Day Range:
$2.3535
$2.44
1-Week Range:
$2.32
$2.575
52-Week Range:
$2.04
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Name
Organogenesis Holdings Inc
Sector
Phone
781-575-0775
Address
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.41 | 310.11M | 514.70M | 2.72M | 17.08M | -0.1589 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Lake Street | Buy |
| Feb-07-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-24-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-19 | Resumed | Credit Suisse | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
| Apr-17-19 | Initiated | Oppenheimer | Outperform |
| Apr-11-19 | Initiated | SunTrust | Buy |
View All
Organogenesis Holdings Inc Stock (ORGO) Latest News
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked - Seeking Alpha
ORGO Q1 2026 Earnings: Significant EPS Miss Highlights Persistent ChallengesEPS Guidance Update - newsline.com
ORGO Q1 2026 Earnings: EPS Misses Estimates by 29.66% as Losses WidenNegative Surprise Momentum - newsline.com
The Body as Blueprint - lifehealth.com
Organogenesis plans rolling BLA submission for ReNu by year-end - Investing.com
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - PR Newswire
Number of shareholders of Organogenesis Holdings, Inc. Class A – DUS:2PQ - TradingView
Organogenesis shares jump 20% following positive clinical trial results - MSN
Organogenesis Holdings Faces Selling Pressure as ORGO Slips to $2.57Oversold Bounce Ideas - newsline.com
Organogenesis Holdings (ORGO) Declines 1.5% as Stock Tests Key Support ZoneFund Manager Survey - The Legal Advocate
Truist initiates Organogenesis stock at Hold on reimbursement shifts - Investing.com UK
Truist initiates Organogenesis stock at Hold on reimbursement shifts By Investing.com - Investing.com India
Truist Initiates Organogenesis Holdings at Hold With $3 Price Target - marketscreener.com
ORGO stock rallies after hours on clearing regulatory pathway for pain relief treatment - MSN
- The Legal Advocate
Organogenesis Holdings (ORGO) Edges Lower as Stock Hovers Near Key SupportBullish Percent Index - The Legal Advocate
Organogenesis rises as PuraPlyAM succeeds in diabetic foot ulcers - MSN
Organogenesis Holdings (ORGO) Holds Steady at $2.66 – Consolidation Phase in PlayALMA Signal - The Legal Advocate
ORGO Q1 2026 Earnings: EPS Falls Short of Estimates Amid Operational ChallengesEPS Miss Report - newsline.com
ORGO Q1 2026 Earnings: Significant EPS Miss Raises ConcernsEarnings Cycle Outlook - newsline.com
Organogenesis Holdings stock (US68620V1026): BTIG rating cut puts focus on outlook after Q1 update - AD HOC NEWS
Is Organogenesis Holdings Inc. (ORGO) Losing Momentum? BTIG Pulls Buy Rating After Q1 Update - Insider Monkey
Organogenesis outlines 2025 revenue guidance of $500M–$525M as CMS policy shift drives growth outlook - MSN
Organogenesis Holdings (ORGO) Q1 2026 Earnings Miss by Significant: Key TakeawaysQuarterly Profit Report - newsline.com
Organogenesis Holdings stock (US68620V1026): FDA warning letter and Nasdaq notice put focus on compl - AD HOC NEWS
Organogenesis Holdings stock (US68620V1026): shares react to earnings and outlook update - AD HOC NEWS
Organogenesis Holdings Inc.Class A (NQ: ORGO - FinancialContent
Organogenesis Holdings stock (US68620V1026): Q1 earnings miss on revenue and EPS - AD HOC NEWS
TradingKey - TradingKey
Organogenesis Holdings Inc. (NASDAQ:ORGO) Q1 2026 Earnings Call Transcript - Insider Monkey
RI skin-maker Organogenesis reports steep Q1 loss amid CMS policy change - The Business Journals
Organogenesis (ORGO) Q1 2026 Earnings Transcript - AOL.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds By Investing.com - Investing.com South Africa
BTIG Downgrades Organogenesis(ORGO.US) to Hold Rating - Moomoo
Organogenesis forecasts $270M-$310M 2026 revenue amid prolonged CMS-related recovery - MSN
symbol__ Stock Quote Price and Forecast - CNN
Organogenesis Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Organogenesis Q1 Earnings Call Highlights - Barchart.com
BTIG downgrades Organogenesis stock rating to neutral on reimbursement headwinds - Investing.com UK
Organogenesis Holdings Inc. (ORGO) Stock Report: Exploring A Potential 216% Upside - DirectorsTalk Interviews
Skin Substitute Market Is Going to Boom Rapidly |Organogenesis - openPR.com
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts By Investing.com - Investing.com South Africa
Earnings call transcript: Organogenesis Q1 2026 earnings miss and stock reacts - Investing.com Australia
Organogenesis Holdings Inc Stock (ORGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Organogenesis Holdings Inc Stock (ORGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):